EUROPEAN JOURNAL OF HEART FAILURE

简称 EUR J HEART FAIL ·NETHERLANDS ·出版周期 Bimonthly ·年均收录 126 篇

10.8

最新影响因子

15.90%

自引率

约25%

投稿难度

平均1月

审稿周期

期刊简介

EUROPEAN JOURNAL OF HEART FAILURE是一本专注于心力衰竭研究的国际学术期刊，ISSN号为1388-9842，由荷兰的ELSEVIER出版社出版，出版周期为月刊，出版地为阿姆斯特丹。该期刊的影响因子较高，属于SCI收录期刊，在中科院分区中通常位于医学领域的较高分区（如1区或2区），但具体分区需根据年度更新确认。该期刊为非OA（开放获取）期刊，但提供部分OA选项。其发文特点集中于心力衰竭的基础与临床研究，涵盖流行病学、病理生理学、诊断、治疗及预后等领域，尤其关注多学科交叉研究和创新性临床实践。杂志以高质量审稿和严谨的学术标准著称，风险较低，但投稿竞争激烈，对研究原创性和方法学要求较高。总体而言，该期刊是心力衰竭领域的权威刊物，适合高水平研究成果的发表。

影响因子趋势

近期发表

Interpreting fragility indices in finerenone trials: complementary insights into statistical stability 2026-06-16

Fragility metrics are the wrong tool for finerenone's cardiovascular evidence 2026-09-12

Mortality benefit and lifetime survival gains with vericiguat in HFrEF: Bayesian and actuarial analyses of the VICTOR trial 2026-09-11

Phenotype-specific prognostic implications of pulse pressure in heart failure 2026-09-05

Correction to: Clinical and cardiac magnetic resonance phenotype of probable viral vs probable immune-mediated acute myocarditis 2026-09-10

Target-dose vs below-target-dose lisinopril and fosinopril in HFrEF with advanced CKD 2026-08-14

Efficacy of Vericiguat by Background Guideline-Directed Medical Therapy in the VICTOR Trial 2026-09-05

Pharmacological optimisation in the treatment of Heart Failure in Women (PopS-HF): rationale and design of a prospective pragmatic, multicentre, randomised trial 2026-09-05

Reply to: Comment on ‘Artificial intelligence fully automated analysis of handheld echocardiography in real-world patients with suspected heart failure’ 2026-09-04

Pulmonary disease: the missing dimension in cardiovascular–kidney–metabolic syndrome 2026-09-04